• Research

    Individual Efficacy of Drug Therapies in Xenograft Models

    Norway’s Karianne Giller Fleten, Christin Lund-Andersen, Annette Torgunrud and Kjersti Flatmark have published a new paper that looks into the individual efficacy of four drug therapies on peritoneal metastases in mouse-human xenograft models: oxaliplatin, irinotecan, cabazitaxel, and regorafenib and capecitabine. The results support the continued exploration of intraperitoneal treatment protocols for peritoneal metastases with oxaliplatin remaining and cabazitaxel emerging as the most interesting candidates for further studies. You can read the new paper here.

  • News

    PSOGI/EURACAN Clinical Practice Guidelines

    A new consensus paper undertaking a complex and thorough investigation into current clinical practice has been released by an international group including many members of EuroPMP. As pseudomyxoma peritonei (PMP) is such a rare disease, it is difficult to find large, randomised trials on which to base treatment decisions. Therefore, using the Delphi consensus model, the Peritoneal Surface Oncology Group International (PSOGI) Executive Committe, which includes may members of EuroPMP, have examined and recommended a new and current best practice for the diagnosis and treatment of PMP. The Delphi decision model was used in conjunction with a broad literature review to come to this agreement, which will now form a…

  • News

    COST Advisory – COVID-19 Outbreak (updated)

    Updated 22 April 2020 at 19:00 (Originally published on 2nd February 2020 at 11:23am) New Information The COST Association has now asked that all face-to-face meetings, STSMs and training schools be cancelled until at least the 30th of April. The use of videoconferencing and other means of communication are recommended. The COST notice may be viewed here.   Previous Information The COST Association has released an advisory note about international travel in the context of the current coronavirus (COVID-19) outbreak. COST has examined the advice of the World Health Organisation (WHO) and national governmental bodies, and has determined that, for the present, international travel does not need to be limited…

  • News

    Twenty-Three Countries Now Acting on PMP

    Since the beginning of the EuroPMP COST Action about 1.5 years ago, the Action has included researchers from many countries, not just in Europe, but around the world. The number of countries now taking part in the action has doubled in the past year alone, and now includes partners from over 23 countries including  Azerbaijan, Bosnia and Herzegovina, Belgium, Germany, Greece, Spain, Finland, France, Croatia, North Macedonia, Ireland, Israel, Italy, Latvia, Montenegro, Norway, Pakistan, Poland, Portugal, Romania, Sweden, Turkey and the United Kingdom. The EuroPMP COST Action aims to increase cooperation between researchers across Europe and around the world to improve research into the cause, detection and treatment of Pseudomyxoma…

  • Events

    Rescheduling of the PMP Workshop

    Save the date! In light of the continuing issues around the COVID-19 pandemic, it has not been possible to reschedule the Pathology Workshop for the near future. Therefore, the Core Committee has proposed a new date of the 10-11th December 2020 for the PMP Pathology Workshop in Basingstoke. As before, the Core Committee will send information to all EuroPMP members closer to the date. If the COVID-19 pandemic has not resolved by this time, the Core Committee may need to reschedule to an even later date. We remain hopeful, however, that the medical emergency will have subsided by December, and so we ask all pathology-interested members to block the time…

  • News

    NORD ACPMP Award for Flatmark Lab

    Prof Kjersti Flatmark’s research group in Oslo have been awarded a NORD ACPMP Research Grant (ID: 19010) to look into the identification of biomarkers in the blood stream of patients. The title of the study is “ctDNA for monitoring patients with pseudomyxoma peritonei”. Pseudomyxoma peritonei (PMP) is a rare abdominal cancer that exhibits specific DNA mutations. After treatment by surgery and intraperitoneal chemotherapy, radiological follow-up has low sensitivity and specificity for detecting disease recurrence. Mutations may be detectible in blood samples, and in this project we will establish and test a method for analyzing circulating tumor DNA (ctDNA) from patients with PMP before and after surgery. If successful, this method…

  • News

    New STSM to Oslo

    Yaroslaw Sautkin, a EuroPMP member from Germany, has completed a Short-Term Scientific Mission to Professor Kjersti Flatmark’s Translational Cancer Therapy lab at Oslo University Hospital’s Institute for Cancer Research. While on his STSM, Yaroslaw learned more about the use of experimental animal models for pseudomyxoma peritonei (PMP) in order to further the work that his own institution, the University of Tübingen, is undertaking into the use of PIPAC with mucolytic substances. Yaroslaw’s visit allowed members of both teams to meet and share knowledge, leading to stronger synergies between their researchers. Both groups are now looking forward to working on research projects together in the future. STSMs are offered several times…

  • Events

    COST Annual General Meeting and Pathology Workshop

    The annual Management Committee and Working Group meeting of the EuroPMP COST Action will take place on the 13th March 2020 in Basingstoke, U.K. A pathology workshop will be held the day before the AGM (12th March), looking into the most recent advances in the field of PMP pathology with speakers from around the world set to take the podium. A draft programme is available here. The meeting and the associated workshop will be held at the Ark Conference Centre, Basingstoke and North Hampshire Hospital, Basingstoke, U.K. The registration form may be accessed here.

  • News

    STSM Call for Applications – Spring 2020

    Short Term Scientific Missions (STSM) are exchange visits between researchers involved in a COST Action, allowing scientists to visit an institution or laboratory in another COST Member state. STSMs are institutional visits aimed at supporting individual mobility, fostering collaboration between individuals. These scientific missions may last from 5 days to up to 6 months. Their aim is to promote collaboration in excellent research infrastructures and share new techniques that may not be available in a participant’s home institution or laboratory. The deadline for the call is 29 February 2020. The STSM itself must take place prior to the end of April 2020. For more information about applying for an STSM,…

  • Research

    Intraperitoneal Mitomycin C Improves Survival in PMP

    EuroPMP’s own Professor Kjersti Flatmark and colleagues have published new findings showing that the use of mitomycin C with intraperitoneal chemotherapy (IPEC) during cytoreductive surgery doubled survival times and reduced tumour growth in a xenograft model when compared to surgery alone. In a signet ring cell model of high-grade PMP, three different methods were tested: normal cytoreductive surgery (CRS), CRS and intraperitoneal chemotherapy of normal temperature and CRS with hyperthermic IPEC (HIPEC). After examination of the methods, it was found that tumour weights were noticeably lower in the groups receiving either IPEC or HIPEC when compared to cytoreductive surgery alone. While more testing will be needed to confirm this finding…